A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue
Locations
Hackensack
Sponsor
Amgen
Protocol Number
20110265
Cancer Diagnosis
To Learn More Call
201-510-0910